Omission of whole-breast RT was associated with higher incidence of recurrence but no difference in survival in patients with lower-risk, ER-positive cancer.
De-escalation of therapy, where appropriate, can potentially have no detrimental effect on outcome while decreasing morbidity and cost. The role of adjuvant breast radiation therapy (RT) in older patients with lower-risk, hormone-sensitive breast cancer has been one such scenario where less is more. Investigators now report mature results from the PRIME II trial, a multicenter, randomized, phase 3 clinical trial of whole-breast RT during 3 to 5 weeks versus no RT. Eligible patients were aged 65 or older with node-negative, estrogen receptor (ER)–positive tumors ≤3 cm who underwent breast-conserving therapy and received adjuvant endocrine therapy. HER2 status was not evaluated at the initiation of the trial.
A total of 1326 patients (median a…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)